Rising Biosciences (Rising Biosciences) Receivables Turnover : 0.00 (As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Rising Biosciences's Revenue for the three months ended in . 20 was $0.00 Mil. Rising Biosciences's average Accounts Receivable for the three months ended in . 20 was $0.00 Mil.

Rising Biosciences Receivables Turnover Historical Data

The historical data trend for Rising Biosciences's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Receivables Turnover Chart

Rising Biosciences Annual Data

Trend

Receivables Turnover

Rising Biosciences Quarterly Data

Receivables Turnover

Competitive Comparison of Rising Biosciences's Receivables Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Rising Biosciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rising Biosciences's Receivables Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rising Biosciences's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Rising Biosciences's Receivables Turnover falls into.

Rising Biosciences Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Rising Biosciences's Receivables Turnover for the fiscal year that ended in . 20 is calculated as

	Receivables Turnover (A: . 20 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: . 20 )	/ (	(Accounts Receivable (A: . 20 )	+	Accounts Receivable (A: . 20 ))	/	count )
=		/ (	(	+	)	/	1 )
=		/	0
=	N/A

Rising Biosciences's Receivables Turnover for the quarter that ended in . 20 is calculated as

	Receivables Turnover (Q: . 20 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: . 20 )	/ (	(Accounts Receivable (Q: . 20 )	+	Accounts Receivable (Q: . 20 ))	/	count )
=		/ (	(	+	)	/	1 )
=		/	0
=	N/A

Rising Biosciences (GREY:RBII) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Rising Biosciences Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Receivables Turnover

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.